The life sciences industry has recently been rocked by dramatic changes in how healthcare is provided, how drugs are developed and researched, the technologies available that enable compani
As we close out the year, pharmaphorum's editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of
Harking back to the Reuters Pharma 2022 event, held at the Nice Acropolis convention centre on France’s South Coast back in October, pharmaphorum had a chance to drop by the booth of EY and
One of the first actions by GSK's recently appointed chief scientific officer, Tony Wood, has been to expand a partnership with Tempus aimed at improving the big pharma's R&D productivi
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte